It has subsequently been found that B-ALL is particularly susceptible to CAR-T cell therapy, much more so than other CD19-positive malignancies such as CLL6,7 and B-lineage lymphomas.8 The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.